{
    "clinical_study": {
        "@rank": "168226", 
        "arm_group": [
            {
                "arm_group_label": "Chemoprohylaxis Group", 
                "arm_group_type": "Active Comparator", 
                "description": "Chemoprohylaxis Group: the treatment group, will be given a single course of methotrexate within fourteen days from molar evacuation. Methotrexate will be given at 0.4 mg/kg intramuscularly per day for 5 days. No chemotherapy will be administered if the hemoglobin is lower than 10 g/L, WBC is less than 3.0 x 10 g/L or more than 10.0 x 10 g/L, absolute neutrophil count is less than 1.5, platelet count is lower than 100,000/cu.cc., patient has elevated liver and renal function test and has concurrent infection."
            }, 
            {
                "arm_group_label": "Control Group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Control Group: will be given a placebo in a form of Vitamin B Complex (Bee ALL), intramuscularly or intravenously."
            }
        ], 
        "brief_summary": {
            "textblock": "A randomized, controlled trial to evaluate the efficacy of methotrexate for the prevention\n      of postmolar gestational trophoblastic disease among patients with high-risk hydatidiform\n      mole."
        }, 
        "brief_title": "RCT on the Efficacy of Methotrexate for the Prevention of GTD", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hydatidiform Mole", 
        "condition_browse": {
            "mesh_term": [
                "Hydatidiform Mole", 
                "Gestational Trophoblastic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "A randomized, controlled trial to evaluate the efficacy of methotrexate for the prevention\n      of postmolar gestational trophoblastic disease among patients with high-risk hydatidiform\n      mole.\n\n      Women who will undergo suction curettage for complete hydatidiform mole at the Philippine\n      General Hospital, who are at risk for developing postmolar gestational trophoblastic disease\n      will be included in the study. Patients will receive either a single course of methotrexate\n      or vitamin B complex (Benutrex) within fourteen days from molar evacuation. Patients' serum\n      beta HCG will be monitored 1 week after molar evacuation and then every 2 weeks until the\n      titers become normal for three consecutive determinations, then monthly for 6 months (every\n      2 months for the next 6 months)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  diagnosis and molar evacuation done at the Department of Obstetrics and Gynecology of\n             the Philippine General Hospital;\n\n          -  patients who will undergo suction curettage for evacuation of molar pregnancy;\n\n          -  histopathologically confirmed complete hydatidiform mole;\n\n          -  must have at least one of the following risk factors for the development of postmolar\n             gestational trophoblastic disease:\n\n               -  uterine size larger than age of gestation of more than 6 weeks\n\n               -  serum B-hCG titer more than or equal to 100,000 mlU/ml\n\n               -  theca lutein cysts more than or equal to 6 cms in size\n\n               -  gravidity of 4 or more\n\n               -  recurrent molar pregnancy\n\n               -  medical complications arising from trophoblastic proliferation such as DIC,\n                  pre-eclampsia, thyrotoxicosis, pulmonary insufficiency\n\n          -  complete data;\n\n          -  patient must have at least one year of regular follow-up and hCG monitoring following\n             onset of remission;\n\n          -  should have signed the consent form.\n\n        Exclusion Criteria:\n\n          -  patients who are lost to follow-up or with incomplete data\n\n          -  patients who underwent total hysterectomy for evacuation of molar pregnancy\n\n          -  patients who are unable to complete the methotrexate treatment\n\n          -  patients who get pregnant within a year following remission\n\n          -  patients with a previous history of gestational trophoblastic neoplasia\n\n          -  patients with medical problems/complications that inhibit administration of\n             methotrexate"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "99", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01984099", 
            "org_study_id": "NIH 2009-044"
        }, 
        "intervention": [
            {
                "arm_group_label": "Chemoprohylaxis Group", 
                "description": "Patients will be given a single course of methotrexate within fourteen days from molar evacuation.", 
                "intervention_name": "Methotrexate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Control Group", 
                "description": "Patients will be given a placebo in a form of Vitamin B Complex (Bee ALL), intramuscularly or intravenously.", 
                "intervention_name": "Vitamin B Complex", 
                "intervention_type": "Drug", 
                "other_name": "Bee ALL"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vitamin B Complex", 
                "Folic Acid", 
                "Vitamins", 
                "Methotrexate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Postmolar Gestational Trophoblastic Disease, Hydatidiform Mole", 
        "lastchanged_date": "November 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Taft Avenue, Ermita, Manila", 
                    "country": "Philippines", 
                    "state": "Manila", 
                    "zip": "1000"
                }, 
                "name": "Philippine General Hospital, University of the Philippines Manila"
            }
        }, 
        "location_countries": {
            "country": "Philippines"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Efficacy of Methotrexate for the Prevention of Postmolar Gestational Trophoblastic Disease Among Patients With High-Risk Hydatidiform Mole", 
        "overall_official": {
            "affiliation": "University of the Philippines Manila", 
            "last_name": "Agnes L. Soriano-Estrella, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Philippines: UP Manila National Institutes of Health - Research Management Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Diagnosis of postmolar gestational trophoblastic diseases will be based on the occurrence of any of the following conditions:\nhigh level of hCG more than 4 weeks post-evacuation (serum level of 20,000mlU/m)\nprogressively increasing or plateuing hCG values at any time after evacuation (minimum of 3 weekly determinations)\nclinical or histologic evidence of metastasis at any site\npersistently elevated hCG titer at 14 weeks post-evacuation\nelevation of previously normal hCG titer after evacuation provided the diagnosis of pregnancy is excluded\nToxicity brought about by the administration of methotrexate will be graded based on the WHO toxicity scoring system.", 
            "measure": "Elevated HCG Level", 
            "safety_issue": "Yes", 
            "time_frame": "4-14 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01984099"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of the Philippines", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of the Philippines", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}